Correlation between Serum Anti-Müllerian Hormone (AMH) Levels and Clinical Severity of Polycystic Ovarian Syndrome (PCOS)

Open Access

Abstract

Background: Polycystic ovary syndrome is an endocrine disorder affecting women of reproductive age, characterized by menstrual irregularities, hyperandrogenism and polycystic ovarian morphology. Anti-Müllerian Hormone reflects ovarian follicular activity and may be associated with PCOS clinical severity. Understanding the relationship between AMH levels and disease manifestations may improve diagnostic strategies. Objective: This study aimed to evaluate the correlation between serum Anti-Müllerian Hormone levels and clinical severity indicators of polycystic ovary syndrome. Methods & Materials: This cross-sectional study was conducted at Update Diagnostic Center, Rangpur, Bangladesh, from June 2024 to July 2025. A total of 120 women were enrolled, including 60 with PCOS and 60 healthy controls. Socio-demographic data, clinical features, anthropometric measurements, hormonal profiles and ultrasonographic parameters were collected. Serum AMH, LH, FSH and testosterone levels were measured using standardized immunoassay methods. Statistical analysis used SPSS version 26.0. Results: PCOS women had higher BMI, waist circumference, menstrual cycle duration and prevalence of clinical manifestations versus controls. Mean serum AMH levels were higher in PCOS patients (7.62 ± 3.21 ng/mL) than in controls (2.71 ± 1.48 ng/mL) (p < 0.001). AMH levels showed positive correlations with BMI (r = 0.28), LH/FSH ratio (r = 0.34), ovarian volume (r = 0.46), antral follicle count (r = 0.52) and Ferriman–Gallwey score (r = 0.31). Conclusion: Serum AMH levels are elevated in women with PCOS and correlate with clinical and hormonal indicators of disease severity.